ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rifampin

Also written as “Rifampicin”, “rifampicin” and “RSS0343 Tablet; Rifampicin Capsules”.

Its studies are mostly in Neoplasms · Tuberculosis, Pulmonary · Hematologic Neoplasms · Melanoma · Bronchiectasis, led by 28 companies.

Drug pageRifampin: every studyMany companies study it; this page follows only the 45 they lead. All 162 studies, academic ones too, with its approvals and label.
Furthest: phase 2, since Sep 25, 200745 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only40 open or runningphase 1since Sep 25, 2007Sep 25, 2007none ahead
AstraZenecaits history only30 open or runningphase 1since Aug 23, 2013Aug 23, 2013none ahead
HUTCHMEDits history only30 open or runningphase 1since Aug 10, 2020Aug 10, 2020none ahead
Jiangsu HengRui Medicineits history only32 open or runningphase 1since Jul 28, 2020Jul 28, 2020none ahead
Takedaits history only30 open or runningphase 1since Jan 23, 2008Jan 23, 2008none ahead
Boehringer Ingelheimits history only20 open or runningphase 1since Jun 20, 2014Jun 20, 2014none ahead
GlaxoSmithKlineits history only20 open or runningphase 2since May 16, 2022Sep 26, 2013none ahead
Hoffmann-La Rocheits history only20 open or runningphase 1since Jan 9, 2013Jan 9, 2013none ahead
Johnson & Johnsonits history only20 open or runningphase 1since Jan 23, 2012Jan 23, 2012none ahead
Pfizerits history only20 open or runningphase 1since Oct 3, 2006Oct 3, 2006none ahead
Vantia10 open or runningphase 1since May 7, 2015May 7, 2015none ahead

Also a collaborator on its studies: Cambridge Cognition, Parexel, Covance and PRA Health Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vantia only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2015First study: phase 1 study in NocturiaFirst studyNCT02440841 · 29 enrolled · Germany

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule

Studies

The one study Vantia leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02440841Nocturia · Germany1CompletedJul 201529

How it is read

Names in the registry

  • “Rifampin”, 18 entries
  • “Rifampicin”, 9 entries
  • “rifampicin”, 5 entries
  • “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
  • “RIFAFOUR e-275”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.